Skip to main content

Table 2 Changes in clinical parameters after administration of n-3 PUFAs

From: N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study

Parameter

Before

After

P-value

BMI (kg/m2)

28.2 ± 5.4

28.0 ± 5.4

0.700

SBP (mmHg)

141.0 ± 7.6

136.0 ± 11.3

0.113

DBP (mmHg)

74.9 ± 11.0

77.9 ± 11.0

0.334

HbA1c (%)

6.9 ± 0.5

7.1 ± 0.6

0.038

FPG (mg/dL)

132.3 ± 18.7

134.7 ± 25.8

0.664

TC (mg/dL)

171.3 ± 21.5

150.5 ± 16.0

< 0.001

LDL-C (mg/dL)

90.3 ± 17.1

79.4 ± 11.4

0.003

HDL-C (mg/dL)

44.9 ± 9.5

45.5 ± 11.3

0.763

TG (mg/dL)

195.7 ± 49.9

128.7 ± 58.8

< 0.001

EPA/AA

0.30 ± 0.19

1.30 ± 0.30

0.008

DHA/AA

0.75 ± 0.16

1.29 ± 0.32

0.008

AST (IU/L)

21.6 ± 6.0

21.8 ± 5.2

0.828

ALT (IU/L)

24.2 ± 6.0

25.4 ± 7.2

0.977

Cre (mg/dL)

0.81 ± 0.32

0.83 ± 0.36

0.539

  1. Data represent the means ± standard deviation. P-values represent differences observed before and after administration of n-3 PUFAs. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, FPG fasting plasma glucose, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglyceride, AST aspartate aminotransferase, ALT alanine aminotransferase, Cre creatinine